AbCellera Biologics (ABCL) PT Raised to $61 at BMO Capital
Tweet Send to a Friend
BMO Capital analyst Do Kim raised the price target on AbCellera Biologics (NASDAQ: ABCL) to $61.00 (from $48.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
